ACRES Commercial Realty Corp.(ACR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACR ACRES Commercial Realty Corp.

Market Closed 12-12 16:00:00 EST

23.71

+0.01

+0.04%

盘后23.71

+0.000.00%

16:04 EST

High23.99	Low23.44	Vol36.99K
Open23.85	D1 Closing23.70	Amplitude2.32%
Mkt Cap172.74M	Tradable Cap172.74M	Total Shares7.29M
T/O880.24K	T/O Rate0.51%	Tradable Shares7.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACR","market":"US","secType":"STK","nameCN":"ACRES Commercial Realty Corp.","latestPrice":23.71,"timestamp":1765573200000,"preClose":23.7,"halted":0,"volume":36994,"hourTrading":{"tag":"盘后","latestPrice":23.71,"preClose":23.71,"latestTime":"16:04 EST","volume":343,"amount":8132.59,"timestamp":1765573444680},"delay":0,"floatShares":7285680,"shares":7285680,"eps":0.953836,"marketStatus":"Market Closed","change":0.01,"latestTime":"12-12 16:00:00 EST","open":23.85,"high":23.99,"low":23.4401,"amount":880244.5479,"amplitude":0.023203,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.953836,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":23.7,"postHourTrading":{"tag":"盘后","latestPrice":23.71,"preClose":23.71,"latestTime":"16:04 EST","volume":343,"amount":8132.59,"timestamp":1765573444680},"volumeRatio":0.7208214789434215,"impliedVol":0.4255,"impliedVolPercentile":0.94},"requestUrl":"/m/hq/s/ACR","defaultTab":"news","newsList":[{"id":"2590287346","title":"Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2590287346","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590287346?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:30","pubTimestamp":1765283400,"startTime":"0","endTime":"0","summary":"Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202247/0/en/Novartis-ianalumab-significantly-extends-disease-control-in-patients-with-immune-thrombocytopenia-with-only-four-once-monthly-doses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP","SLE","BK4109","ACR","ASH","BK4110","BK4077","LU2463526074.USD"],"gpt_icon":0},{"id":"2584906256","title":"Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584906256","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584906256?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:56","pubTimestamp":1763607360,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 , ATG-037 , and ATG-101 . The company will also share the latest progress on ATG-125 :A B7H3 x PD-L1 targeted therapy featuring\"IO + ADC\"dual-effect molecules for the treatment of solid tumors and its AnTenGagerT-cell engager  technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs.In addition, guest expert Prof. Xin Wang, Chief Physician, Drug Clinical Trial Center, National Cancer Center / Cancer Hospital of the Chinese Academy of Medica","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-hosts-2025-rd-day-showcasing-encouraging-clinical-data-and-solid-progress-with-investigational-programs-302621100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK4187","IND.AU","CRS.AU","IE00B7SZL793.SGD","BK7508","ACR","IE00B66KJ199.SGD","LU0963586101.USD","CR","CRS","LU2065732104.USD","PRGS","ACR.AU","ORR.AU","BK4161","BK4006","BK4110","LU2065731478.USD","BK4097","ORR","BK7096","IE0031619046.USD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2583966185","title":"Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583966185","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583966185?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040600,"startTime":"0","endTime":"0","summary":"Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187342/24675/en/Fate-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","BK4205","BK4022","IE00B66KJ199.SGD","BK4233","BK4230","UK","CRS","LU0963586101.USD","BK4139","IE00B7SZL793.SGD","CAR","IIM","LU0266512127.USD","BK4077","BK4213","BK4187","LU0456854461.SGD","BK4109","ACR","IE0031619046.USD","CRC","BK4110","LU2065731478.USD","BK4006","SLE","IE00B19Z4B17.USD","EMA","BK4528","BK4081","FATE","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2581762102","title":"Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762102","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762102?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:15","pubTimestamp":1762290900,"startTime":"0","endTime":"0","summary":"Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180905/0/en/Anaptys-Announces-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEP","BK4144","ACR","GPP","BK4110","BK4590"],"gpt_icon":0},{"id":"2580644330","title":"ACRES Commercial Realty Corp. Reports Positive Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2580644330","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580644330?lang=en_us&edition=fundamental","pubTime":"2025-11-01 08:29","pubTimestamp":1761956977,"startTime":"0","endTime":"0","summary":"Acres Commercial Realty Corp. (($ACR)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for ACR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acres-commercial-realty-corp-reports-positive-q3-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acres-commercial-realty-corp-reports-positive-q3-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACR"],"gpt_icon":0},{"id":"2579464089","title":"Acres Commercial Realty Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2579464089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579464089?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:57","pubTimestamp":1761915420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2025 08:57 ET (12:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","ACR"],"gpt_icon":0},{"id":"2579452037","title":"ACRES Commercial Realty Corp. price target raised to $24.50 from $23.50 at Citizens JMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2579452037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579452037?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:05","pubTimestamp":1761905152,"startTime":"0","endTime":"0","summary":"Citizens JMP raised the firm’s price target on ACRES Commercial Realty Corp. (ACR) to $24.50 from $23.50 and keeps an Outperform rating on the shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acres-commercial-realty-corp-price-target-raised-to-24-50-from-23-50-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acres-commercial-realty-corp-price-target-raised-to-24-50-from-23-50-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACR","JMP"],"gpt_icon":0},{"id":"1134217316","title":"ACRES Realty Q3 2025 Earnings Call Summary and Q&A Highlights: Strategic Asset Sales and Book Value Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1134217316","media":"Earnings Call","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134217316?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:56","pubTimestamp":1761836195,"startTime":"0","endTime":"0","summary":"[Management View]The management reported a net loan portfolio decrease of $46.8 million in Q3 2025, driven by $106.4 million in new loan commitments and $153.2 million in loan payoffs, sales, and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR"],"gpt_icon":0},{"id":"2579269021","title":"ACRES Realty (ACR) Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2579269021","media":"Motley Fool Transcribing","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579269021?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:52","pubTimestamp":1761835945,"startTime":"0","endTime":"0","summary":"DATEThursday, October 30, 2025 at 10 a.m. ETCALL PARTICIPANTSChief Executive Officer and President — Mark Steven FogelChief Financial Officer — Eldron C. BlackwellChairman — Andrew Dodd FentressManaging Director — Kyle K. BrengelNeed a quote from a Motley Fool analyst?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_motley_transcript","url":"https://www.fool.com/earnings/call-transcripts/2025/10/30/acres-realty-acr-earnings-call-transcript/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/10/30/acres-realty-acr-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["ACR"],"gpt_icon":0},{"id":"2579513627","title":"ACRES Commercial Realty Q3 Sales $21.037M Miss $22.151M Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2579513627","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579513627?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:30","pubTimestamp":1761769826,"startTime":"0","endTime":"0","summary":"ACRES Commercial Realty (NYSE:ACR) reported quarterly sales of $21.037 million which missed the analyst consensus estimate of $22.151 million by 5.03 percent. This is a 5.89 percent decrease over sales of $22.353 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/10/48512463/acres-commercial-realty-q3-sales-21-037m-miss-22-151m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ACRES Commercial Realty Q3 Sales $21.037M Miss $22.151M Estimate.","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","ACR"],"gpt_icon":0},{"id":"2579133748","title":"Acres Commercial Realty reports Q3 net income of $9.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2579133748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579133748?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:10","pubTimestamp":1761768635,"startTime":"0","endTime":"0","summary":"Acres Commercial Realty Corp. reported GAAP net income allocable to common shares of $9.8 million, or $1.34 per diluted share, for the third quarter ended September 30, 2025. During the quarter, the company sold one of its real estate investments to utilize deferred tax assets, with the proceeds redeployed into new loans. Acres Commercial Realty Corp. stated its intention to continue growing its portfolio in the fourth quarter and beyond by investing in new loan opportunities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acres Commercial Realty Corp. published the original content used to generate this news brief via PR Newswire  on October 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL9BrFJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","BK4110"],"gpt_icon":0},{"id":"2579139159","title":"Acres Commercial Realty Corp - Reports $9.8 Mln Net Income, $1.34 per Share  for Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2579139159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579139159?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:10","pubTimestamp":1761768601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nPLX44DE1A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACR","BK4110"],"gpt_icon":0},{"id":"2579182133","title":"Acres Commercial Realty Corp. Reports Results for Third Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579182133","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579182133?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:10","pubTimestamp":1761768600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA9MYYGZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACR","BK4110"],"gpt_icon":0},{"id":"2579900527","title":"Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2579900527","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579900527?lang=en_us&edition=fundamental","pubTime":"2025-10-29 22:30","pubTimestamp":1761748200,"startTime":"0","endTime":"0","summary":"NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1Data showed consistentimprovementsacross secondary outcome measures, and a f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176619/0/en/Novartis-ianalumab-first-drug-to-reduce-disease-activity-and-patient-burden-in-Sj%C3%B6gren-s-disease-Phase-III-trials.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4110","ITP","SLE","ACR","BK4199","BK4077","BK4134"],"gpt_icon":0},{"id":"2579790195","title":"Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2579790195","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579790195?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:15","pubTimestamp":1761743700,"startTime":"0","endTime":"0","summary":"New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced thera","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176538/0/en/Anaptys-Announces-New-Positive-Phase-2b-Trial-Results-for-Rosnilimab-in-Rheumatoid-Arthritis-at-ACR-Late-Breaking-Oral-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","ACR","BK4110"],"gpt_icon":0},{"id":"2578951877","title":"Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2578951877","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578951877?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:15","pubTimestamp":1761653700,"startTime":"0","endTime":"0","summary":"Ness-Ziona, Israel, Oct.  28, 2025  (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/28/3175403/0/en/Enlivex-Therapeutics-to-Present-Phase-IIa-3-month-Data-of-Allocetra-in-Patients-with-Moderate-to-Severe-Knee-Osteoarthritis-at-the-ACR-Convergence-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","BK4539","LENZ","BK4007","ACR","BK4139"],"gpt_icon":0},{"id":"1170133925","title":"QYUNS-B (02509): QX002N (Lusekizumab) Phase III Clinical Trial Results for Ankylosing Spondylitis Presented at 2025 ACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1170133925","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170133925?lang=en_us&edition=fundamental","pubTime":"2025-10-28 17:56","pubTimestamp":1761645383,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on October 27, 2025, the Phase III clinical trial results of its self-developed drug, QX002N (Lusekizumab), for the treatment of ankylosing spondylitis (AS) were...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","BK4134","III","BK4110","BK1161","02509"],"gpt_icon":0},{"id":"2578677499","title":"Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications","url":"https://stock-news.laohu8.com/highlight/detail?id=2578677499","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578677499?lang=en_us&edition=fundamental","pubTime":"2025-10-28 07:18","pubTimestamp":1761607129,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics, Inc. (($ACRV)) announced an update on their ongoing clinical study. Study Overview: Acrivon Therapeutics, Inc. is conducting ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acrivon-therapeutics-phase-1-study-of-acr-2316-key-updates-and-market-implications?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acrivon-therapeutics-phase-1-study-of-acr-2316-key-updates-and-market-implications?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","BK4007","BK4110","ACR"],"gpt_icon":0},{"id":"2578064963","title":"Acres Commercial Realty Corp  expected to post earnings of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2578064963","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578064963?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:44","pubTimestamp":1761569056,"startTime":"0","endTime":"0","summary":"Acres Commercial Realty Corp  expected to post earnings of11cents a share - Earnings Preview Acres Commercial Realty Corp ACR.N, ACR is expected to  show a fall in quarterly revenue when it reports  r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nL8N3W80ZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","BK4110"],"gpt_icon":0},{"id":"2578648653","title":"Tonix Pharmaceuticals presents data on Tonmya at ACR Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2578648653","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578648653?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:16","pubTimestamp":1761563794,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals (TNXP) presented data on Tonmya, which was investigated as TNX-102 SL, at the 2025 American College of Rheumatology Convergen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tonix-pharmaceuticals-presents-data-on-tonmya-at-acr-convergence-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tonix-pharmaceuticals-presents-data-on-tonmya-at-acr-convergence-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4110","ACR","TNXP","BK4583","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acresreit.com","stockEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":0.1023},{"period":"3month","weight":0.1405},{"period":"6month","weight":0.3165},{"period":"1year","weight":0.3833},{"period":"ytd","weight":0.4681}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ACRES Commercial Realty Corp., a real estate investment trust (REIT), focuses on the origination, holding, and management of commercial real estate mortgage loans and equity investments in commercial real estate property in the United States. It invests in commercial real estate-related assets, including floating-rate first mortgage loans, first priority interests in first mortgage loans, subordinated interests in first mortgage loans, mezzanine financing, preferred equity investments, and commercial mortgage-backed securities. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as Exantas Capital Corp. and changed its name to ACRES Commercial Realty Corp. in February 2021. ACRES Commercial Realty Corp. was incorporated in 2005 and is based in Uniondale, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.012017},{"month":2,"riseRate":0.578947,"avgChangeRate":-0.003152},{"month":3,"riseRate":0.5,"avgChangeRate":0.025933},{"month":4,"riseRate":0.55,"avgChangeRate":-0.00119},{"month":5,"riseRate":0.4,"avgChangeRate":-0.037047},{"month":6,"riseRate":0.55,"avgChangeRate":0.132395},{"month":7,"riseRate":0.6,"avgChangeRate":-0.003891},{"month":8,"riseRate":0.55,"avgChangeRate":0.035284},{"month":9,"riseRate":0.4,"avgChangeRate":-0.015744},{"month":10,"riseRate":0.4,"avgChangeRate":0.001876},{"month":11,"riseRate":0.45,"avgChangeRate":0.006419},{"month":12,"riseRate":0.4,"avgChangeRate":0.014174}],"exchange":"NYSE","name":"ACRES Commercial Realty Corp.","nameEN":"ACRES Commercial Realty Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACRES Commercial Realty Corp.(ACR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACRES Commercial Realty Corp.(ACR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACRES Commercial Realty Corp.,ACR,ACRES Commercial Realty Corp.股票,ACRES Commercial Realty Corp.股票老虎,ACRES Commercial Realty Corp.股票老虎国际,ACRES Commercial Realty Corp.行情,ACRES Commercial Realty Corp.股票行情,ACRES Commercial Realty Corp.股价,ACRES Commercial Realty Corp.股市,ACRES Commercial Realty Corp.股票价格,ACRES Commercial Realty Corp.股票交易,ACRES Commercial Realty Corp.股票购买,ACRES Commercial Realty Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACRES Commercial Realty Corp.(ACR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACRES Commercial Realty Corp.(ACR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction